IMMUTEP LIMITED - Announcements

Market Cap $428.5M Add to my watchlist

Healthcare Biotechnology

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

IMM	Appendix 3B		28/05/15	675.24KB	Share
IMM	Becoming a substantial holder		27/05/15	72.89KB	Share
IMM	Cleansing Notice & Appendix 3B		27/05/15	666.96KB	Share
IMM	Appendix 3B		26/05/15	675.63KB	Share
IMM	Appendix 3B		25/05/15	676.16KB	Share
IMM	Prima to Present at Proactive Investors Forums		25/05/15	208.91KB	Share
IMM	Prima to Commercialise Database Management Platform	PRICE SENSITIVE	25/05/15	211.54KB	Share
IMM	Cleansing Notice		20/05/15	195.06KB	Share
IMM	Prima May 2015 Corporate Presentation		20/05/15	1.91MB	Share
IMM	Prima 2015 Capital Raising Presentation		20/05/15	858.88KB	Share
IMM	CVac shows overall survival benefit	PRICE SENSITIVE	19/05/15	310.62KB	Share
IMM	Change of registry address		15/05/15	159.85KB	Share
IMM	Information Required Under Listing Rule 3.10.5A		15/05/15	237.77KB	Share
IMM	Appendix 3B		15/05/15	901.54KB	Share
IMM	Prima Biomed Announces A$15m Investment from Ridgeback	PRICE SENSITIVE	14/05/15	113.41KB	Share
IMM	Prima announces Japanese Collaboration	PRICE SENSITIVE	11/05/15	91.21KB	Share
IMM	Prima to present at Canary Networks Investor Roadshow		29/04/15	204.78KB	Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	16/04/15	349.79KB	Share
IMM	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/15	367.43KB	Share
IMM	Prima BioMed Prioritising IMP 321	PRICE SENSITIVE	27/02/15	215.34KB	Share
IMM	Detailed Investor Presentation		27/02/15	1.11MB	Share
IMM	Introductory Investor Presentation		27/02/15	1.38MB	Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/15	191.19KB	Share
IMM	Financial milestone payment to be received from GSK	PRICE SENSITIVE	27/01/15	280.94KB	Share
IMM	Cleansing Notice & Appendix 3B		23/01/15	296.25KB	Share
IMM	R&D Tax Incentive Refund Received	PRICE SENSITIVE	20/01/15	112.21KB	Share
IMM	Stuart Roberts appointed Global Head of Investor Relations		20/01/15	216.93KB	Share
IMM	Change of Director's Interest Notice		07/01/15	293.18KB	Share
IMM	Prima receives NASDAQ deficiency notice		29/12/14	128.09KB	Share
IMM	Notice of Grant received from Canadian Patent Office	PRICE SENSITIVE	22/12/14	213.27KB	Share
IMM	Prima completes acquisition of Immutep	PRICE SENSITIVE	17/12/14	210.39KB	Share
IMM	Prima initiates Pancreatic Clinical Trial with CVac	PRICE SENSITIVE	15/12/14	221.08KB	Share
IMM	Appendix 3B		12/12/14	684.88KB	Share
IMM	Cleansing Notice & Appendix 3B		12/12/14	715.55KB	Share
IMM	Cleansing Notice & Appendix 3B		11/12/14	715.88KB	Share
IMM	Enhancement of manufacturing and logistics capabilities	PRICE SENSITIVE	05/12/14	205.77KB	Share
IMM	Change of Director's Interest Notice		28/11/14	327.5KB	Share
IMM	Appendix 3B		28/11/14	707.3KB	Share
IMM	Results of Meeting		14/11/14	205.78KB	Share
IMM	2014 AGM Presentations		14/11/14	1.62MB	Share
IMM	2014 AGM Chairman's Address		14/11/14	205.98KB	Share
IMM	Society for Immunotherapy of Cancer poster presentation		10/11/14	240.3KB	Share
IMM	Cleansing Notice & Appendix 3B		06/11/14	527.69KB	Share
IMM	CVac demonstrates overall survival benefit	PRICE SENSITIVE	06/11/14	230.84KB	Share
IMM	Supplemental Information for Shareholder Conference Call		23/10/14	851.82KB	Share
IMM	Conference Call to discuss acquisition of Immutep		21/10/14	215.18KB	Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	21/10/14	345.81KB	Share
IMM	Notice of Allowance for IMP321 Patent	PRICE SENSITIVE	14/10/14	210.4KB	Share
IMM	Prima Newsletter		13/10/14	1.03MB	Share
IMM	Notice of Annual General Meeting/Proxy Form		13/10/14	638.28KB	Share
IMM	Annual Report to Shareholders		10/10/14	2.52MB	Share
IMM	Annual Report on Form 20-F filed with SEC		10/10/14	1.44MB	Share
IMM	Cleansing Notice & Appendix 3B		02/10/14	518.33KB	Share
IMM	Prima secures funding from US institutional investor		02/10/14	244.84KB	Share
IMM	Proposed Acquisition of Immutep	PRICE SENSITIVE	02/10/14	239.63KB	Share
IMM	Appendix 3B		19/09/14	437.58KB	Share
IMM	Appendix 4E & 2014 Full Year Statutory Accounts	PRICE SENSITIVE	27/08/14	769.04KB	Share
IMM	Prima to present at Society for Immunotherapy of Cancer		19/08/14	205.37KB	Share
IMM	Prima Newsletter		31/07/14	619.57KB	Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/14	382.74KB	Share
IMM	CEO Terms of Employment		22/07/14	211.57KB	Share
IMM	Prima receives US patent grant for CVac	PRICE SENSITIVE	16/07/14	206.12KB	Share
IMM	Initial Director's Interest Notice		15/07/14	187.51KB	Share
IMM	Final Director's Interest Notice		15/07/14	201.57KB	Share
IMM	Prima appoints new CEO	PRICE SENSITIVE	09/07/14	209.81KB	Share
IMM	Journal for Immunotherapy of Cancer Publication		23/06/14	316.99KB	Share
IMM	Prima to present at 2014 WAGO Annual Meeting		19/06/14	207.05KB	Share
IMM	Transcript of CAN-003 data conference call		04/06/14	188.08KB	Share
IMM	Supplemental information for CAN-003 data conference call		02/06/14	644.03KB	Share
IMM	Q&A with Dr Gray on CAN-003 data presented at ASCO		02/06/14	501.72KB	Share
IMM	CVac demonstrates positive trend in Overall Survival	PRICE SENSITIVE	02/06/14	226.44KB	Share
IMM	Conference call to discuss CAN-003 data presented at ASCO		30/05/14	340.25KB	Share
IMM	USA Patent for CVac Allowed	PRICE SENSITIVE	26/05/14	205.81KB	Share
IMM	CVac demonstrates clinically meaningful improvement in PFS	PRICE SENSITIVE	15/05/14	230.3KB	Share
IMM	Prima BioMed's CVac granted Fast Track Designation by FDA	PRICE SENSITIVE	09/05/14	329.12KB	Share
IMM	Supplemental Information for Quarterly Conference Call	PRICE SENSITIVE	06/05/14	621.96KB	Share
IMM	Prima Newsletter		05/05/14	322.98KB	Share
IMM	Third Quarter Conference Call		29/04/14	228.81KB	Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/14	383.53KB	Share
IMM	Prima commences recruitment for CAN 004 Phase 2 trial	PRICE SENSITIVE	28/04/14	210.52KB	Share
IMM	Prima to present at Needham Healthcare Conference		07/04/14	204.56KB	Share
IMM	CVac Improvement in 2nd Remission Data Accepted for ASCO	PRICE SENSITIVE	28/03/14	208.97KB	Share
IMM	New Appointments to Clinical Advisory Board		25/03/14	213.2KB	Share
AAI +PRX ADS ADO AEH CQE AFJ AGI AVR AJD ALK ALU AMX ANI AOH AQG AQP ARP PRN ASZ ATU AVG AXZ BGA BNO BOL BTR BYI CAJ CCU CLE CFU COF CPL CRH CTP CUE CVO DCG DDR DLX DML DSH DYL EAX K2P EPW EQX WJA EVR EWC FLK FLN RHK FND NOU FSA GAP GBG GBT GCS GDI ETM GHC GID GJT GNG GOW GDA GRY GUF GXY HIG HPI IAG E88 ICN ICQ IDC DXI IPP ISN JHX JPR KPL KRL KRM VBC LSA MCE MCR MCS MEO AZT LCL SYM MNW SVR MOY MPO MRP MVP MYE NCM NCR NEA NEN NEU NSE NSR NXS OFX OMH OZL PAN PBD ATH PCL PEN PGH OVT IMM QAN AX1 REA RKN RXP SAO SBB SDF SDM SEH SHJ SIV KLS SLR SMX SWL TAP TBR TFC TGP TGZ AUK UGL VAH VED VEI VET VLW VOC VTG WBA WDS XRO ZNZ ZSP	S&P DJ Indices Announces March Quarterly Rebalance		07/03/14	98KB	Share
IMM	$1.6 million R&D Tax Incentive Refund Received	PRICE SENSITIVE	05/03/14	200.07KB	Share
IMM	Prima to present at Regen Med Investor Day		27/02/14	215.94KB	Share
IMM	Prima to present at Wall Street Analyst Forum		27/02/14	208.05KB	Share
IMM	Prima and Neopharm execute final CVac licensing agreement	PRICE SENSITIVE	21/02/14	208.75KB	Share
IMM	Dr Monk to Join Prima BioMed Clinical Advisory Board		20/02/14	212.75KB	Share
IMM	Half Yearly Report and Accounts	PRICE SENSITIVE	18/02/14	2.47MB	Share
IMM	Appendix 3X		13/02/14	197.28KB	Share
IMM	Appendix 3Z		13/02/14	201KB	Share
IMM	Appointment & Retirement of Non-Executive Director		12/02/14	209.22KB	Share
IMM	Supplemental Information for Quarterly Conference Call		06/02/14	308.6KB	Share
IMM	CAN-004 Amendment Approved in Multiple Jurisdictions	PRICE SENSITIVE	06/02/14	209.83KB	Share
IMM	Prima to present at Annual BIO CEO & Investor Conference		31/01/14	208.02KB	Share
IMM	Second Quarter Highlights and Conference Call		29/01/14	480.02KB	Share
IMM	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/14	384.75KB	Share
IMM	Appendix 3B		24/01/14	433.73KB	Share
IMM	Prima CEO to be interviewed on live US Radio Show		09/01/14	383.45KB	Share

IMM Appendix 3B
28/05/15		675.24KB	Share
IMM Becoming a substantial holder
27/05/15		72.89KB	Share
IMM Cleansing Notice & Appendix 3B
27/05/15		666.96KB	Share
IMM Appendix 3B
26/05/15		675.63KB	Share
IMM Appendix 3B
25/05/15		676.16KB	Share
IMM Prima to Present at Proactive Investors Forums
25/05/15		208.91KB	Share
IMM Prima to Commercialise Database Management Platform
25/05/15	PRICE SENSITIVE	211.54KB	Share
IMM Cleansing Notice
20/05/15		195.06KB	Share
IMM Prima May 2015 Corporate Presentation
20/05/15		1.91MB	Share
IMM Prima 2015 Capital Raising Presentation
20/05/15		858.88KB	Share
IMM CVac shows overall survival benefit
19/05/15	PRICE SENSITIVE	310.62KB	Share
IMM Change of registry address
15/05/15		159.85KB	Share
IMM Information Required Under Listing Rule 3.10.5A
15/05/15		237.77KB	Share
IMM Appendix 3B
15/05/15		901.54KB	Share
IMM Prima Biomed Announces A$15m Investment from Ridgeback
14/05/15	PRICE SENSITIVE	113.41KB	Share
IMM Prima announces Japanese Collaboration
11/05/15	PRICE SENSITIVE	91.21KB	Share
IMM Prima to present at Canary Networks Investor Roadshow
29/04/15		204.78KB	Share
IMM Appendix 4C - quarterly
16/04/15	PRICE SENSITIVE	349.79KB	Share
IMM Half Yearly Report and Accounts
27/02/15	PRICE SENSITIVE	367.43KB	Share
IMM Prima BioMed Prioritising IMP 321
27/02/15	PRICE SENSITIVE	215.34KB	Share
IMM Detailed Investor Presentation
27/02/15		1.11MB	Share
IMM Introductory Investor Presentation
27/02/15		1.38MB	Share
IMM Appendix 4C - quarterly
30/01/15	PRICE SENSITIVE	191.19KB	Share
IMM Financial milestone payment to be received from GSK
27/01/15	PRICE SENSITIVE	280.94KB	Share
IMM Cleansing Notice & Appendix 3B
23/01/15		296.25KB	Share
IMM R&D Tax Incentive Refund Received
20/01/15	PRICE SENSITIVE	112.21KB	Share
IMM Stuart Roberts appointed Global Head of Investor Relations
20/01/15		216.93KB	Share
IMM Change of Director's Interest Notice
07/01/15		293.18KB	Share
IMM Prima receives NASDAQ deficiency notice
29/12/14		128.09KB	Share
IMM Notice of Grant received from Canadian Patent Office
22/12/14	PRICE SENSITIVE	213.27KB	Share
IMM Prima completes acquisition of Immutep
17/12/14	PRICE SENSITIVE	210.39KB	Share
IMM Prima initiates Pancreatic Clinical Trial with CVac
15/12/14	PRICE SENSITIVE	221.08KB	Share
IMM Appendix 3B
12/12/14		684.88KB	Share
IMM Cleansing Notice & Appendix 3B
12/12/14		715.55KB	Share
IMM Cleansing Notice & Appendix 3B
11/12/14		715.88KB	Share
IMM Enhancement of manufacturing and logistics capabilities
05/12/14	PRICE SENSITIVE	205.77KB	Share
IMM Change of Director's Interest Notice
28/11/14		327.5KB	Share
IMM Appendix 3B
28/11/14		707.3KB	Share
IMM Results of Meeting
14/11/14		205.78KB	Share
IMM 2014 AGM Presentations
14/11/14		1.62MB	Share
IMM 2014 AGM Chairman's Address
14/11/14		205.98KB	Share
IMM Society for Immunotherapy of Cancer poster presentation
10/11/14		240.3KB	Share
IMM Cleansing Notice & Appendix 3B
06/11/14		527.69KB	Share
IMM CVac demonstrates overall survival benefit
06/11/14	PRICE SENSITIVE	230.84KB	Share
IMM Supplemental Information for Shareholder Conference Call
23/10/14		851.82KB	Share
IMM Conference Call to discuss acquisition of Immutep
21/10/14		215.18KB	Share
IMM Appendix 4C - quarterly
21/10/14	PRICE SENSITIVE	345.81KB	Share
IMM Notice of Allowance for IMP321 Patent
14/10/14	PRICE SENSITIVE	210.4KB	Share
IMM Prima Newsletter
13/10/14		1.03MB	Share
IMM Notice of Annual General Meeting/Proxy Form
13/10/14		638.28KB	Share
IMM Annual Report to Shareholders
10/10/14		2.52MB	Share
IMM Annual Report on Form 20-F filed with SEC
10/10/14		1.44MB	Share
IMM Cleansing Notice & Appendix 3B
02/10/14		518.33KB	Share
IMM Prima secures funding from US institutional investor
02/10/14		244.84KB	Share
IMM Proposed Acquisition of Immutep
02/10/14	PRICE SENSITIVE	239.63KB	Share
IMM Appendix 3B
19/09/14		437.58KB	Share
IMM Appendix 4E & 2014 Full Year Statutory Accounts
27/08/14	PRICE SENSITIVE	769.04KB	Share
IMM Prima to present at Society for Immunotherapy of Cancer
19/08/14		205.37KB	Share
IMM Prima Newsletter
31/07/14		619.57KB	Share
IMM Appendix 4C - quarterly
31/07/14	PRICE SENSITIVE	382.74KB	Share
IMM CEO Terms of Employment
22/07/14		211.57KB	Share
IMM Prima receives US patent grant for CVac
16/07/14	PRICE SENSITIVE	206.12KB	Share
IMM Initial Director's Interest Notice
15/07/14		187.51KB	Share
IMM Final Director's Interest Notice
15/07/14		201.57KB	Share
IMM Prima appoints new CEO
09/07/14	PRICE SENSITIVE	209.81KB	Share
IMM Journal for Immunotherapy of Cancer Publication
23/06/14		316.99KB	Share
IMM Prima to present at 2014 WAGO Annual Meeting
19/06/14		207.05KB	Share
IMMTranscript of CAN-003 data conference call
04/06/14		188.08KB	Share
IMMSupplemental information for CAN-003 data conference call
02/06/14		644.03KB	Share
IMMQ&A with Dr Gray on CAN-003 data presented at ASCO
02/06/14		501.72KB	Share
IMMCVac demonstrates positive trend in Overall Survival
02/06/14	PRICE SENSITIVE	226.44KB	Share
IMMConference call to discuss CAN-003 data presented at ASCO
30/05/14		340.25KB	Share
IMMUSA Patent for CVac Allowed
26/05/14	PRICE SENSITIVE	205.81KB	Share
IMMCVac demonstrates clinically meaningful improvement in PFS
15/05/14	PRICE SENSITIVE	230.3KB	Share
IMMPrima BioMed's CVac granted Fast Track Designation by FDA
09/05/14	PRICE SENSITIVE	329.12KB	Share
IMMSupplemental Information for Quarterly Conference Call
06/05/14	PRICE SENSITIVE	621.96KB	Share
IMMPrima Newsletter
05/05/14		322.98KB	Share
IMMThird Quarter Conference Call
29/04/14		228.81KB	Share
IMMAppendix 4C - quarterly
29/04/14	PRICE SENSITIVE	383.53KB	Share
IMMPrima commences recruitment for CAN 004 Phase 2 trial
28/04/14	PRICE SENSITIVE	210.52KB	Share
IMMPrima to present at Needham Healthcare Conference
07/04/14		204.56KB	Share
IMMCVac Improvement in 2nd Remission Data Accepted for ASCO
28/03/14	PRICE SENSITIVE	208.97KB	Share
IMMNew Appointments to Clinical Advisory Board
25/03/14		213.2KB	Share
AAI +PRX ADS ADO AEH CQE AFJ AGI AVR AJD ALK ALU AMX ANI AOH AQG AQP ARP PRN ASZ ATU AVG AXZ BGA BNO BOL BTR BYI CAJ CCU CLE CFU COF CPL CRH CTP CUE CVO DCG DDR DLX DML DSH DYL EAX K2P EPW EQX WJA EVR EWC FLK FLN RHK FND NOU FSA GAP GBG GBT GCS GDI ETM GHC GID GJT GNG GOW GDA GRY GUF GXY HIG HPI IAG E88 ICN ICQ IDC DXI IPP ISN JHX JPR KPL KRL KRM VBC LSA MCE MCR MCS MEO AZT LCL SYM MNW SVR MOY MPO MRP MVP MYE NCM NCR NEA NEN NEU NSE NSR NXS OFX OMH OZL PAN PBD ATH PCL PEN PGH OVT IMM QAN AX1 REA RKN RXP SAO SBB SDF SDM SEH SHJ SIV KLS SLR SMX SWL TAP TBR TFC TGP TGZ AUK UGL VAH VED VEI VET VLW VOC VTG WBA WDS XRO ZNZ ZSPS&P DJ Indices Announces March Quarterly Rebalance
07/03/14		98KB	Share
IMM$1.6 million R&D Tax Incentive Refund Received
05/03/14	PRICE SENSITIVE	200.07KB	Share
IMMPrima to present at Regen Med Investor Day
27/02/14		215.94KB	Share
IMMPrima to present at Wall Street Analyst Forum
27/02/14		208.05KB	Share
IMMPrima and Neopharm execute final CVac licensing agreement
21/02/14	PRICE SENSITIVE	208.75KB	Share
IMMDr Monk to Join Prima BioMed Clinical Advisory Board
20/02/14		212.75KB	Share
IMMHalf Yearly Report and Accounts
18/02/14	PRICE SENSITIVE	2.47MB	Share
IMMAppendix 3X
13/02/14		197.28KB	Share
IMMAppendix 3Z
13/02/14		201KB	Share
IMMAppointment & Retirement of Non-Executive Director
12/02/14		209.22KB	Share
IMMSupplemental Information for Quarterly Conference Call
06/02/14		308.6KB	Share
IMMCAN-004 Amendment Approved in Multiple Jurisdictions
06/02/14	PRICE SENSITIVE	209.83KB	Share
IMMPrima to present at Annual BIO CEO & Investor Conference
31/01/14		208.02KB	Share
IMMSecond Quarter Highlights and Conference Call
29/01/14		480.02KB	Share
IMMAppendix 4C - quarterly
29/01/14	PRICE SENSITIVE	384.75KB	Share
IMMAppendix 3B
24/01/14		433.73KB	Share
IMMPrima CEO to be interviewed on live US Radio Show
09/01/14		383.45KB	Share

REFRESH

First 7 8 9 10 11

(20min delay)
Last 29.5¢		Change 0.000(0.00%)		Mkt cap ! $428.5M

Open	High	Low	Value	Volume
30.0¢	30.5¢	29.0¢	$732.3K	2.454M

Buyers (Bids)

No.	Vol.	Price($)
2	113261	29.5¢

Sellers (Offers)

Price($)	Vol.	No.
30.5¢	169614	3

View Market Depth

No.	Vol.	Price($)
1	13261	0.295
16	654614	0.290
21	379613	0.285
29	1373806	0.280
6	191364	0.275

Price($)	Vol.	No.
0.305	169614	3
0.310	180851	7
0.315	368109	3
0.320	139107	4
0.325	10000	1

Last trade - 16.10pm 22/07/2024 (20 minute delay)


Last 30.0¢		Change 0.000 ( 1.56 %)
Open	High	Low	Volume
30.5¢	30.5¢	29.5¢	811598
Last updated 15.59pm 22/07/2024 ?

IMM (ASX) Chart

IMMUTEP LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available